$7.25 -0.59 (-7.67%)

Gyre Therapeutics, Inc. Common Stock (GYRE)

Gyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies targeting neurological and neurodegenerative disorders. Utilizing advanced drug delivery platforms, Gyre aims to address unmet medical needs through novel treatments that improve patient outcomes.

Dividend Yield 0%
Payout Frequency

Dividend History

Pay Date Amount Ex-Date Record Date
January 12, 2023 $0.24 2023-01-13 2023-01-05
September 20, 2022 $1.43 2022-09-21 2022-09-06
August 19, 2015 $0.57 2015-08-20 2015-08-14

Dividends Summary

Company News

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
GlobeNewswire Inc. • Gyre Therapeutics • August 22, 2025

Gyre Therapeutics announced the appointment of Dr. Dan Weng to its Board of Directors, bringing nearly four decades of clinical trial management experience. The company is focused on developing fibrosis treatments and has a prominent product in the Chinese market.

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga • Avi Kapoor • April 11, 2024

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents. Fastenal shares dipped 6.7% to $69.73 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Rallybio Corporation (NASDAQ: RLYB) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rent the Runway, Inc. (NASDAQ: RENT) shares jumped 74.5% to $12.91 after the company reported mixed fourth-quarter financial results and issued guidance. Eliem Therapeutics, Inc. (NASDAQ: ELYM) jumped 59.6% to $4.2650. The company announced that it entered into a definitive acquisition agreement to acquire Tenet and it also entered into a securities purchase agreement for a $120 million private placement. Akanda Corp. (NASDAQ: AKAN) gained 36% to $0.1632. Akanda, last month, announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry. Alpine Immune Sciences, Inc. (NASDAQ: ALPN) rose 36.6% to $64.25 after Vertex entered into an agreement to acquire the company. Candel Therapeutics, Inc. (NASDAQ: CADL) surged 29.6% to $6.61 after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. Enliven Therapeutics, Inc. (NASDAQ: ELVN) gained 26% to $24.97. Enliven Therapeutics announced proof ...

Is It Time to Buy the Nasdaq's 5 Worst-Performing Stocks in February 2024?
The Motley Fool [email protected] (Anders Bylund) • February 7, 2024

Some Nasdaq stocks are soaring in 2024, but these five charts are down by 40% or more. Are any of these struggling stocks actually good buys at a low price?